CN103845354A - Pharmaceutical composition containing gentiopicroside and its preparation and use - Google Patents
Pharmaceutical composition containing gentiopicroside and its preparation and use Download PDFInfo
- Publication number
- CN103845354A CN103845354A CN201210499871.3A CN201210499871A CN103845354A CN 103845354 A CN103845354 A CN 103845354A CN 201210499871 A CN201210499871 A CN 201210499871A CN 103845354 A CN103845354 A CN 103845354A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- preparation
- application
- gentiopicrin
- swertiamarin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention belongs to the technical field of medicine and discloses a pharmaceutical composition containing gentiopicroside and its preparation and use. The pharmaceutical composition contains gentiopicroside, swertiamarin and loganic acid. The pharmaceutical composition is determined by a science experiment. An experiment proves that swertiamarin and loganic acid do not influence stability of gentiopicroside. A pharmacological test proves that the pharmaceutical composition produces synergism.
Description
Technical field
The invention belongs to medical technical field, be specifically related to a kind of pharmaceutical composition that contains gentiopicrin active component and preparation and purposes.
Background technology
Liver be in health take metabolic function as a main organ, and playing the part of deoxidation in health the inside, storing the effect such as synthetic of glycogen, secreted protein.Liver is the organ that body weight for humans is wanted, and wherein hepatitis is commonly encountered diseases, frequently-occurring disease, and its type mainly contains three: one, viral hepatitis, the 2nd, alcoholic hepatitis, the 3rd, drug induced hepatitis.The traditional Chinese medical science is referred to as jaundice.Modal in clinical is viral hepatitis.The hepatitis acute attack stage traditional Chinese medical science is often called " YANG jaundice ", and acute hepatitis transfers chronic hepatitis to or the PCH traditional Chinese medical science is called " YIN jaundice ".Hepatitis virus carrier accounts for total crowd's 46%, and sickness rate is 15%, that is to say that it is hepatitis patients that approximately there are 200,000,000 people in the whole nation.China is that whole world hepatitis endangers maximum country, and sickness rate ranks first in the world.Having a strong impact on the healthy of people, is the significant problem that must cause that colleague pays close attention to.Just because of above-mentioned reason, countries in the world, each large pharmacy corporation are all in the searching for the treatment of hepatitis medicine of throwing oneself into.China is except schizandrol, bifendate, zinc glycyrrhetate, silibinin single or single component, and Chinese medicine compound is not lower hundreds of, in the symptom of hepatitis alleviates and treats, has played positive role.But the healing degree to hepatitis is far from satisfactory.These medicines are mostly oral formulations, and injection is less, all exist treatment cycle long, control the imprecise drawback of effect.
Gentiopicrin forms from the medicinal material extract such as Radix Gentianae Macrophyllae are refining, and relevant gentiopicrin pharmacodynamics aspect research is both at home and abroad more, is mainly hepatic cholagogic aspect report, and pharmacological toxicology and clinical experimental study show that gentiopicrin is safe and effective.Gentiopicrin can increase bile cholesterol and bilirubinic excretion, can improve Na
+, K
+the activity of-ATP enzyme.Can obviously reduce ALT, AST and LDH, to hepatic tissue pathology, damage has certain improvement effect.Gentiopicrin also can suppress the generation of TNF in serum, shows that gentiopicrin is by suppressing TNF, and suppresses hepatitis.
Therefore, take gentiopicrin as material base, carry out deep exploitation, will there is deep scientific meaning.
Summary of the invention
For these reasons, applicant, by the test of science, determines take gentiopicrin as basis, finds a kind of new pharmaceutical composition, and this pharmaceutical composition comprises gentiopicrin, swertiamarin and lognic acid; Stability test shows, swertiamarin and lognic acid for gentiopicrin stability without any impact; Pharmacodynamics test shows, this pharmaceutical composition has collaborative pharmacological action.
The present invention realizes by following proposal.
A kind of pharmaceutical composition, is characterized in that pharmaceutical composition comprises gentiopicrin, swertiamarin and lognic acid.
A kind of pharmaceutical composition, pharmaceutical composition comprises gentiopicrin and swertiamarin and lognic acid.
Wherein in pharmaceutical composition, gentiopicrin weight content is for being more than or equal to 90% and be less than 100%, and swertiamarin weight content is greater than 0 and be less than or equal to 4%, and lognic acid weight content is greater than 0 and be less than or equal to 6%.
Wherein in pharmaceutical composition, gentiopicrin weight content is for being more than or equal to 90% and be less than 100%, and swertiamarin weight content is greater than 0 and be less than or equal to 6%, and lognic acid weight content is greater than 0 and be less than or equal to 4%.
Wherein in pharmaceutical composition, gentiopicrin weight content is for being more than or equal to 90% and be less than 100%, and swertiamarin weight content is greater than 0 and be less than or equal to 9%, and lognic acid weight content is greater than 0 and be less than or equal to 1%.
A kind of pharmaceutical composition described above is the pharmaceutical preparation that raw material is prepared into.
Wherein preparation comprises oral formulations.
Wherein preparation comprises ejection preparation.
A kind of pharmaceutical composition described above is in the application of preparing in hepatic.
Pharmaceutical composition described above is in the application of preparing in function of gallbladder promoting medicine.
Pharmaceutical composition described above application in preparation antiviral drugs.
Pharmaceutical composition described above application in preparation treatment hepatitis B medicine.
Pharmaceutical composition described above is in the application of preparing in Hepatoma therapy medicine.
Pharmaceutical preparation described above, wherein oral formulations comprises tablet or capsule.
Pharmaceutical preparation described above, wherein ejection preparation comprises lyophilized injectable powder.
One, stability test
1, trial drug:
Test 1 group: gentiopicrin.
Test 2 groups: swertiamarin.
Test 3 groups: lognic acid.
Test 4 groups: gentiopicrin 9.2g, swertiamarin 0.5g, lognic acid 0.3g, mix homogeneously, for subsequent use.
2, test method:
(1) exposure experiments to light: get different tests sample, loose dividing in little culture dish, the about 5mm of thickness.Be placed on the proof box of medicine strong illumination (SHH-100GD, Chongqing immortality experimental apparatus factory; LHH-250GP, upper sea blue leopard testing equipment company limited), under illumination 4500Lx ± 500Lx condition, to place 10 days, sampling in the 10th day, detects, and result is compared with 0 month data.Result of the test is in table 1.
(2) hot test: sample thief, is placed in small beaker, diaphragm seal sealing.Be placed on electric drying oven with forced convection (DHG-9023A, Shanghai Yi Heng Science and Technology Ltd.), under 60 ℃ ± 1 ℃ condition, place 10 days, sampling in 10 days detects, and result is compared with 0 month data.Result of the test is in table 2.
(3) high wet test: sample thief, be placed in small beaker, be placed in respectively and fill NaCl saturated solution and KNO
3the close drying device of saturated solution, damp condition is respectively RH75%.It is placed in respectively to electric drying oven with forced convection (DHG-9023A, Shanghai Yi Heng Science and Technology Ltd.), under 25 ℃ ± 1 ℃ condition, places 10 days, sampling in the 10th day detects, and result is compared with 0 month data.Result of the test is in table 3.
3, detection method:
(1) gentiopicrin detection method
Measure according to high performance liquid chromatography (appendix VI D of " Chinese Pharmacopoeia " version in 2010).
Chromatographic condition and system suitability experiment are filler with octadecylsilane chemically bonded silica; Take methanol-water (3: 7) as mobile phase; Detection wavelength is 270nm.Number of theoretical plate is pressed gentiopicrin peak and is calculated, and should be not less than 3000.
It is appropriate that the preparation precision of reference substance solution takes gentiopicrin reference substance, adds mobile phase and make the solution of every 1ml containing 0.5mg, to obtain final product.
It is appropriate that the preparation precision of need testing solution takes this product, adds mobile phase and make the solution of every 1ml containing 0.5mg, to obtain final product.
Algoscopy is accurate reference substance solution and the each 10 μ l of need testing solution of drawing respectively, and injection liquid chromatography, measures, and to obtain final product.
(2) swertiamarin detection method
Measure according to high performance liquid chromatography (appendix VI D of " Chinese Pharmacopoeia " version in 2010).
Chromatographic condition and system suitability experiment are filler with octadecylsilane chemically bonded silica; Take methanol-water (3: 7) as mobile phase; Detection wavelength is 236nm.
It is appropriate that the preparation precision of reference substance solution takes swertiamarin reference substance, adds mobile phase and make the solution of every 1ml containing 0.5mg, to obtain final product.
It is appropriate that the preparation precision of need testing solution takes this product, adds mobile phase and make the solution of every 1ml containing 0.5mg, to obtain final product.
Algoscopy is accurate reference substance solution and the each 10 μ l of need testing solution of drawing respectively, and injection liquid chromatography, measures, and to obtain final product.
(3) lognic acid detection method
Measure according to high performance liquid chromatography (appendix VI D of " Chinese Pharmacopoeia " version in 2010).
Chromatographic condition and system suitability experiment are filler with octadecylsilane chemically bonded silica; Take methanol-0.5% acetic acid water (25: 75) as mobile phase; Detection wavelength is 238nm.
It is appropriate that the preparation precision of reference substance solution takes lognic acid reference substance, adds mobile phase and make the solution of every 1ml containing 0.5mg, to obtain final product.
It is appropriate that the preparation precision of need testing solution takes this product, adds mobile phase and make the solution of every 1ml containing 0.5mg, to obtain final product.
Algoscopy is accurate reference substance solution and the each 10 μ l of need testing solution of drawing respectively, and injection liquid chromatography, measures, and to obtain final product.
4, testing result:
Table 1 exposure experiments to light result
Table 2 hot test result
Table 3 high humidity result of the test
Conclusion (of pressure testing): aforementioned stable test shows, gentiopicrin and swertiamarin are carried out to compatibility, and high temperature, high humidity, high light do not affect for the two content, illustrate gentiopicrin and swertiamarin the two aspect stability without interaction.
Two, pharmacological test example
Embodiment 1
To the protective effect of isolated liver cell apoptosis
Experimental animal: Kunming mouse, male, 4 week age.
Trial drug:
1 group of trial drug: gentiopicrin 30mg/kg.
2 groups of trial drugs: swertiamarin 30mg/kg.
3 groups of trial drugs: gentiopicrin 27.2mg/kg, swertiamarin 1.2mg/kg, lognic acid 1.6mg/kg.
4 groups of trial drugs: gentiopicrin 27.2mg/kg, swertiamarin 1.6mg/kg, lognic acid 1.2mg/kg.
Test reagent: formaldehyde; CoulterDNA-PrepReagentsKit test kit (DNA-PrepLPR fixative, DNA-Prepstain dyestuff).
Test apparatus: autobalance micro centrifuge; Flow cytometer.
Test method: by mice random packet: Normal group, model group, trial drug group.Administration group tail vein injection every day gives relative medicine, dosage 30mg/kg, and Normal group, model group tail vein injection every day such as give at the capacity normal saline, 7d continuously, fasting (freely drinking water) 12h before administration in the 7th day, after administration 2h, de-cervical vertebra is put to death animal.Respectively get 2mm × 2mm × 1mm left and right fritter leftlobe of liver tissue, add 5ml normal saline, on 200 mesh filter screens, grind, and constantly filter, blow and beat into unicellular, the centrifugal 5min of 4000r/min, abandoning supernatant, residual liquid shakes even, get 10 μ l Cell saps, Normal group adds 5mlNS, all the other each group respectively adds 5ml1% formaldehyde, 2～4 ℃ of cold preservation 15min, the centrifugal 5min of 4000r/min, abandoning supernatant, residual liquid adds respectively 5ml normal saline and cleans, centrifugal, remove supernatant, each Guan Jun washes 2 times, abandoning supernatant, residual liquid adds 50 μ lDNA-PrepLPR fixatives, vibration, add 450 μ lDNA-Prepstain dyestuffs, lucifuge 30min, detect with flow cytometer.
Result of the test: the results are shown in Table 4.
The impact of table 4 on each group of isolated liver cell cycle and apoptosis
Note: with relatively * * P < 0.01 of model group; Compare #P < 0.05 with 1 group of test; Compare %P < 0.05 with 2 groups of tests.
Embodiment 2
To CCl
4cause the protective effect of acute liver
Experimental animal: KM mice, rank: healthy secondary, the age: 6.5 ± 0.5 weeks, sex: male and female half and half, body weight: 20 ± 2g.
Trial drug:
1 group of trial drug: gentiopicrin 30mg/kg.
2 groups of trial drugs: swertiamarin 30mg/kg.
3 groups of trial drugs: gentiopicrin 27.0mg/kg, swertiamarin 2.7mg/kg, lognic acid 0.3mg/kg.
4 groups of trial drugs: gentiopicrin 27.5mg/kg, swertiamarin 2.4mg/kg, lognic acid 0.1mg/kg.
Test reagent: CCl
4; Olive oil.
Test method: mice is pressed to body weight random packet: blank group, model group, trial drug 1-4 group, male and female half and half.Each administration group is pressed trial drug group tail intravenously administrable, and blank group and model group give isopyknic distilled water, every day 1 time, continuous 7 days.20:00 removed food on 1, and after 8:00 weighed on 1, once, 16:00 abdominal cavity gives 0.1%CCl to tail intravenously administrable
410ml/kg, blank group gives isopyknic olive oil with method, within 8th, weighs and gets fasting blood, and separation of serum, measures each group of Serum ALT and AST.
Result of the test: the results are shown in Table 5.
Table 5 is to CCl
4cause acute liver impact
Note: with relatively * * P < 0.01 of model group; Compare #P < 0.05 with 1 group of test; Compare %P < 0.05 with 2 groups of tests.
Embodiment 3
To the protective effect of rat chronic hepatic injury
Experimental animal: Wistar rat, male, body weight: 200 ± 2g.
Trial drug:
1 group of trial drug: gentiopicrin 20mg/kg.
2 groups of trial drugs: swertiamarin 20mg/kg.
3 groups of trial drugs: gentiopicrin 18mg/kg, swertiamarin 1.0mg/kg, lognic acid 1.0mg/kg.
4 groups of trial drugs: gentiopicrin 18.7mg/kg, swertiamarin 0.9mg/kg, lognic acid 0.4mg/kg.
Test reagent: CCl
4; Olive oil.
Test method: rat is pressed to body weight random packet: normal group, model group, trial drug group.Except blank group, other respectively organize subcutaneous injection 40%CCl
4olive oil solution 5ml/kg, later subcutaneous injection 40%CCl weekly
4olive oil solution 3ml/kg twice, continues 6 weeks, and blank group gives the olive oil of same volume.Simultaneously all the other each group according to identical pharmaceutical quantities tail every day intravenously administrable 1 time, and successive administration 6 weeks, weighs weekly once, adjusts dosage according to the variation of body weight.After last administration 24 hours, get the blood sample of animal, separation of serum is measured respectively ALT, AST, TP and Alb by automatic clinical chemistry analyzer.The animal of drug withdrawal time daily femoral artery sacrificed by exsanguination, is cooked substantially and histopathologic examination.Measure weight and the coefficient of liver, spleen; Take out each treated animal liver, the conventional dehydration of leftlobe of liver, embedding and section, histological examination is done in HE dyeing.
Result of the test: the results are shown in Table 6, table 7.
The impact of table 6 different pharmaceutical on rat liver coefficient
Note: with relatively * * P < 0.01 of model group, * P < 0.05; Compare #P < 0.05 with 1 group of test; Compare %P < 0.05 with 2 groups of tests.
The impact of table 7 on rat blood biochemical indicator and Liver hydroxyproline content
Note: with relatively * * P < 0.01 of model group, * P < 0.05; Compare #P < 0.05 with 1 group of test; Compare %P < 0.05 with 2 groups of tests.
Embodiment 4
On the impact of rat bile secretion
Experimental animal: Wistar rat, rank: healthy secondary, the age: 7 ± 0.5 months, sex: male, body weight: 310 ± 30g.
Trial drug:
1 group of trial drug: gentiopicrin 20mg/kg.
2 groups of trial drugs: swertiamarin 20mg/kg.
3 groups of trial drugs: gentiopicrin 18mg/kg, swertiamarin 1.0mg/kg, lognic acid 1.0mg/kg.
4 groups of trial drugs: gentiopicrin 18.7mg/kg, swertiamarin 0.9mg/kg, lognic acid 0.4mg/kg.
Test reagent: urethanes (urethane); Sodium chloride injection.
Test apparatus: electronic balance; Air dry oven; The portable sterilizer of coal and electricity dual-purpose.
Test method: rat fasting be can't help water 12 hours, lumbar injection 20% urethane solution (5ml/kg) anesthesia, face upward position fixing, routine disinfection, at the otch that cuts 2cm along ventrimeson, open abdominal cavity, in descendant duodenum mesentery, find the bile duct of white flexible, separate bile duct, will, near the firm ligation in duodenal one end, do a v-notch with eye scissors to liver direction from the nearly duodenum seam of bile duct, capillary plastic tube is inserted in common bile duct, visible have pistac bile to flow out, and ligation fixed plastics pipe, collects bile with small beaker.
Rat is divided into blank group at random by body weight, trial drug group.Used after operation hemostasis clamp closes abdominal cavity, cover with saline gauze, after stablizing 20min, first collect 30min bile, then respectively organize rat tail vein administration, blank group gives distilled water, trial drug group dosage is 20mg/kg, and after administration, every 30min measures bile once, totally 4 times, record the bile volume of each group of rat administration front and back, bile secretion percentage rate after calculating administration.
Result of the test: the results are shown in Table 8.
The impact of table 8 on rat bile flow
Note: with relatively * * P < 0.01 of model group, * P < 0.05; Compare #P < 0.05 with 1 group of test; Compare %P < 0.05 with 2 groups of tests.
Embodiment 5
Hepatitis virus resisting effect
Experimental animal: Beijing duck.
Trial drug:
1 group of trial drug: gentiopicrin 204.0mg/kg, swertiamarin 4.2mg/kg, lognic acid 1.8mg/kg.
4 groups of trial drugs: gentiopicrin 204.0mg/kg, swertiamarin 4.2mg/kg, lognic acid 1.8mg/kg, magnesium isoglycyrrhetate 1mg.
Test reagent: DHBV-DNA is positive, and Sanguis Anas domestica is clear.
Test apparatus: probe.
Test method: get Beijing duck, clear through the positive Sanguis Anas domestica of lower limb shin intravenous injection DHBV-DNA, every 0.3ml, infects and get blood in latter 7 days, and separation of serum detects DHBV-DNA content in serum.Sanguis Anas domestica after DHBV is positive clearly after testing, is divided into group at random by duck: virus control group, trial drug group, and respectively organize lumbar injection and give medicine, every day 2 times, dosage 210mg/kg, matched group gives same volume normal saline, successive administration 10 days.Respectively with Drug therapy after after 5 days (T5), 10 days (T10) and drug withdrawal 3 days (P3) from duck shin venous blood sampling, separation of serum, press nick translation test kit description method, with 32P labelling DHBV-DNA probe, and make the clear dot blot hybridization of Sanguis Anas domestica, and autoradiography diaphragm speckle, microplate reader is measured OD value (optical filter is 490nm), calculate serum DHBV-DNA optical density, using hybridization spot OD value as specimen DHBV-DNA level value.
Result of the test: the results are shown in Table 9.
Table 9 is the impact on DHV DHBV-DNA in duck body
Note: with relatively * * P < 0.01 of T0 group.
Two, toxicology test example
Test example 1
To the acute toxicity test of mice
Experimental animal: ICR Strains of Mouse, 18-22g.
Trial drug:
Test 1 group: gentiopicrin.
Test 2 groups: gentiopicrin 0.75g, swertiamarin 0.15g, lognic acid 0.10g.
Test 3 groups: gentiopicrin 0.90g, swertiamarin 0.06g, lognic acid 0.04g.
Test 4 groups: gentiopicrin 0.935g, swertiamarin 0.005g, lognic acid 0.06.
Test method: get ICR mice, before experiment, the about 15h of water is can't help in fasting, is divided into 25 groups (6 groups of every trial drug groups, 1 group of matched group).The administration of each group mouse tail vein, test 1 group and be all according to dosage respectively 300mg/kg, 450mg/kg, 900mg/kg, 1500mg/kg, 2100mg/kg, 2700mg/kg (be equivalent to respectively intend quantity 10,15,30,50,70,90 times) to testing 4 groups of dosages, control group mice gives same volume distilled water.Examine and record toxic reaction and death condition that administration occurs to mice in 7d at once; Adopt Bliss ' s method to calculate LD50.
Result of the test: in table 10.
The LD50 comparison of table 10 different tests group medicine
| Group | mg/kg |
| Test 1 group | 2809.94±193.394 |
| Test 2 groups | 1664.92±124.769 |
| Test 3 groups | 2345.34±133.213 |
| Test 4 groups | 2011.41±125.781 |
Conclusion (of pressure testing): above-mentioned acute toxicity test shows, medicine (gentiopicrin) LD50 that does not contain swertiamarin and lognic acid exceedes 2500mg/kg, and along with the content of lognic acid in compositions increases, its LD50 is more and more less, therefore, in preferred composition, lognic acid content is no more than 6%.
Sum up: above-mentioned pharmacodynamics test and toxicology test show, in preferred pharmaceutical composition of the present invention wherein in pharmaceutical composition gentiopicrin weight content for being more than or equal to 90% and be less than 100%, swertiamarin weight content is greater than 0 and be less than or equal to 4%, and lognic acid weight content is greater than 0 and be less than or equal to 6%.
Preparation Example
Embodiment 1
A kind of pharmaceutical composition, gentiopicrin 74g in pharmaceutical composition, swertiamarin 4g, lognic acid 2mg; Add mannitol 90g; Be prepared into 1000 of lyophilized injectable powders.
This pharmaceutical composition is for the application at preparation treatment hepatic.
Pharmaceutical composition described above is in the application of preparing in function of gallbladder promoting medicine.
The application of aforementioned pharmaceutical compositions in preparation antiviral drugs.
Pharmaceutical composition described above application in preparation treatment hepatitis B medicine.
Pharmaceutical composition described above is in the application of preparing in Hepatoma therapy medicine.
Embodiment 2
A kind of pharmaceutical composition, gentiopicrin 72g in pharmaceutical composition, swertiamarin 4g, lognic acid 4g; Add mannitol 90g; Be prepared into 1000 of lyophilized injectable powders.
This pharmaceutical composition is for the application at preparation treatment hepatic.
Pharmaceutical composition described above is in the application of preparing in function of gallbladder promoting medicine.
The application of aforementioned pharmaceutical compositions in preparation antiviral drugs.
Pharmaceutical composition described above application in preparation treatment hepatitis B medicine.
Pharmaceutical composition described above is in the application of preparing in Hepatoma therapy medicine.
Embodiment 3
A kind of pharmaceutical composition, gentiopicrin 79.0g in pharmaceutical composition, swertiamarin 0.8g, lognic acid 0.2g; Add mannitol 90g; Be prepared into 1000 of lyophilized injectable powders.
This pharmaceutical composition is for the application at preparation treatment hepatic.
Pharmaceutical composition described above is in the application of preparing in function of gallbladder promoting medicine.
The application of aforementioned pharmaceutical compositions in preparation antiviral drugs.
Pharmaceutical composition described above application in preparation treatment hepatitis B medicine.
Pharmaceutical composition described above is in the application of preparing in Hepatoma therapy medicine.
Embodiment 4
A kind of pharmaceutical composition, gentiopicrin 315.0g in pharmaceutical composition, swertiamarin 3.2g, lognic acid 1.8g; Add lactose 2150g, low-substituted hydroxypropyl cellulose 113g, magnesium stearate 10g, is prepared into 5000, tablet.
This pharmaceutical composition is for the application at preparation treatment hepatic.
Pharmaceutical composition described above is in the application of preparing in function of gallbladder promoting medicine.
The application of aforementioned pharmaceutical compositions in preparation antiviral drugs.
Pharmaceutical composition described above application in preparation treatment hepatitis B medicine.
Pharmaceutical composition described above is in the application of preparing in Hepatoma therapy medicine.
Embodiment 5
A kind of pharmaceutical composition, gentiopicrin 374g in pharmaceutical composition, swertiamarin 2g, lognic acid 24g; Add lactose 2146g, low-substituted hydroxypropyl cellulose 112g, magnesium stearate 11g, is prepared into 5000, tablet.
This pharmaceutical composition is for the application at preparation treatment hepatic.
Pharmaceutical composition described above is in the application of preparing in function of gallbladder promoting medicine.
The application of aforementioned pharmaceutical compositions in preparation antiviral drugs.
Pharmaceutical composition described above application in preparation treatment hepatitis B medicine.
Pharmaceutical composition described above is in the application of preparing in Hepatoma therapy medicine.
Embodiment 6
A kind of pharmaceutical composition, gentiopicrin 363g in pharmaceutical composition, swertiamarin 36g, lognic acid 1g; Add lactose 2146g, low-substituted hydroxypropyl cellulose 115g, magnesium stearate 13g, is prepared into 5000, tablet.
This pharmaceutical composition is for the application at preparation treatment hepatic.
Pharmaceutical composition described above is in the application of preparing in function of gallbladder promoting medicine.
The application of aforementioned pharmaceutical compositions in preparation antiviral drugs.
Pharmaceutical composition described above application in preparation treatment hepatitis B medicine.
Pharmaceutical composition described above is in the application of preparing in Hepatoma therapy medicine.
Embodiment 7
A kind of pharmaceutical composition, gentiopicrin 316.0g in pharmaceutical composition, swertiamarin 3.2g, lognic acid 0.8g, is prepared into 5000 of aqueous injection.
This pharmaceutical composition is for the application at preparation treatment hepatic.
Pharmaceutical composition described above is in the application of preparing in function of gallbladder promoting medicine.
The application of aforementioned pharmaceutical compositions in preparation antiviral drugs.
Pharmaceutical composition described above application in preparation treatment hepatitis B medicine.
Pharmaceutical composition described above is in the application of preparing in Hepatoma therapy medicine.
Embodiment 8
A kind of pharmaceutical composition, gentiopicrin 396g in pharmaceutical composition, swertiamarin 2g, lognic acid 2g; Be prepared into 5000 of aqueous injection.
This pharmaceutical composition is for the application at preparation treatment hepatic.
Pharmaceutical composition described above is in the application of preparing in function of gallbladder promoting medicine.
The application of aforementioned pharmaceutical compositions in preparation antiviral drugs.
Pharmaceutical composition described above application in preparation treatment hepatitis B medicine.
Pharmaceutical composition described above is in the application of preparing in Hepatoma therapy medicine.
Embodiment 9
A kind of pharmaceutical composition, gentiopicrin 363g in pharmaceutical composition, swertiamarin 36g, lognic acid 1g; Be prepared into 5000 of aqueous injection.
This pharmaceutical composition is for the application at preparation treatment hepatic.
Pharmaceutical composition described above is in the application of preparing in function of gallbladder promoting medicine.
The application of aforementioned pharmaceutical compositions in preparation antiviral drugs.
Pharmaceutical composition described above application in preparation treatment hepatitis B medicine.
Pharmaceutical composition described above is in the application of preparing in Hepatoma therapy medicine.
Embodiment 10
A kind of pharmaceutical composition, gentiopicrin 362g in pharmaceutical composition, swertiamarin 30g, lognic acid 2g, kurarinone 2g, adds mannitol 465g, is prepared into 5000 of lyophilized injectable powders.
This pharmaceutical composition is for the application at preparation treatment hepatic.
Pharmaceutical composition described above is in the application of preparing in function of gallbladder promoting medicine.
The application of aforementioned pharmaceutical compositions in preparation antiviral drugs.
Pharmaceutical composition described above application in preparation treatment hepatitis B medicine.
Pharmaceutical composition described above is in the application of preparing in Hepatoma therapy medicine.
Embodiment 11
A kind of pharmaceutical composition, gentiopicrin 371g in pharmaceutical composition, swertiamarin 20g, lognic acid 1g, kurarinone 8g, adds mannitol 452g, is prepared into 5000 of lyophilized injectable powders.
This pharmaceutical composition is for the application at preparation treatment hepatic.
Pharmaceutical composition described above is in the application of preparing in function of gallbladder promoting medicine.
The application of aforementioned pharmaceutical compositions in preparation antiviral drugs.
Pharmaceutical composition described above application in preparation treatment hepatitis B medicine.
Pharmaceutical composition described above is in the application of preparing in Hepatoma therapy medicine.
Embodiment 12
A kind of pharmaceutical composition, gentiopicrin 396g in pharmaceutical composition, swertiamarin 2g, lognic acid 1g, kurarinone 1g, adds mannitol 446g, is prepared into 5000 of lyophilized injectable powders.
This pharmaceutical composition is for the application at preparation treatment hepatic.
Pharmaceutical composition described above is in the application of preparing in function of gallbladder promoting medicine.
The application of aforementioned pharmaceutical compositions in preparation antiviral drugs.
Pharmaceutical composition described above application in preparation treatment hepatitis B medicine.
Pharmaceutical composition described above is in the application of preparing in Hepatoma therapy medicine.
Described embodiment includes but not limited to above-mentioned.
Claims (14)
1. a pharmaceutical composition, is characterized in that pharmaceutical composition comprises gentiopicrin and swertiamarin and lognic acid.
2. a kind of pharmaceutical composition according to claim 1, wherein in pharmaceutical composition gentiopicrin weight content for being more than or equal to 90% and be less than 100%, swertiamarin weight content is greater than 0 and be less than or equal to 4%, and lognic acid weight content is greater than 0 and be less than or equal to 6%.
3. a kind of pharmaceutical composition according to claim 1, wherein in pharmaceutical composition gentiopicrin weight content for being more than or equal to 90% and be less than 100%, swertiamarin weight content is greater than 0 and be less than or equal to 6%, and lognic acid weight content is greater than 0 and be less than or equal to 4%.
4. a kind of pharmaceutical composition according to claim 1, wherein in pharmaceutical composition gentiopicrin weight content for being more than or equal to 90% and be less than 100%, swertiamarin weight content is greater than 0 and be less than or equal to 9%, and lognic acid weight content is greater than 0 and be less than or equal to 1%.
5. be the pharmaceutical preparation that raw material is prepared into according to a kind of pharmaceutical composition described in claim 1-4 any one.
6. pharmaceutical preparation according to claim 5, wherein preparation comprises oral formulations.
7. pharmaceutical preparation according to claim 5, wherein preparation comprises ejection preparation.
According to a kind of pharmaceutical composition described in claim 1-4 any one in the application of preparing in hepatic.
According to the pharmaceutical composition described in claim 1-4 any one in the application of preparing in function of gallbladder promoting medicine.
10. the application in preparation antiviral drugs according to the pharmaceutical composition described in claim 1-4 any one.
11. application in preparation treatment hepatitis B medicine according to the pharmaceutical composition described in claim 1-4 any one.
12. according to the pharmaceutical composition described in claim 1-4 any one in the application of preparing in Hepatoma therapy medicine.
13. pharmaceutical preparatioies according to claim 6, wherein oral formulations comprises tablet or capsule.
14. pharmaceutical preparatioies according to claim 7, wherein ejection preparation comprises lyophilized injectable powder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210499871.3A CN103845354A (en) | 2012-11-30 | 2012-11-30 | Pharmaceutical composition containing gentiopicroside and its preparation and use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210499871.3A CN103845354A (en) | 2012-11-30 | 2012-11-30 | Pharmaceutical composition containing gentiopicroside and its preparation and use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103845354A true CN103845354A (en) | 2014-06-11 |
Family
ID=50853759
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210499871.3A Pending CN103845354A (en) | 2012-11-30 | 2012-11-30 | Pharmaceutical composition containing gentiopicroside and its preparation and use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103845354A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104478894A (en) * | 2014-12-30 | 2015-04-01 | 云南中医学院 | Gnetiolactone compound, as well as preparation method and application thereof |
| CN108042559A (en) * | 2018-01-08 | 2018-05-18 | 西安正大制药有限公司 | A kind of new Macrophylla dragon capsule optimizes pharmaceutical composition and its in analgesia, anti-inflammatory, in terms of cholagogic application |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1590398A (en) * | 2004-05-28 | 2005-03-09 | 胡少勇 | Preparation of gentian effective part and its application |
| CN101396428A (en) * | 2007-09-30 | 2009-04-01 | 中国科学院西北高原生物研究所 | Tibetan capillary extract and preparation method, medicine composition and use thereof |
| CN101830892A (en) * | 2010-05-19 | 2010-09-15 | 重庆市中药研究院 | Method for separating glycoside chemical components from tibetan capillaris |
-
2012
- 2012-11-30 CN CN201210499871.3A patent/CN103845354A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1590398A (en) * | 2004-05-28 | 2005-03-09 | 胡少勇 | Preparation of gentian effective part and its application |
| CN101396428A (en) * | 2007-09-30 | 2009-04-01 | 中国科学院西北高原生物研究所 | Tibetan capillary extract and preparation method, medicine composition and use thereof |
| CN101830892A (en) * | 2010-05-19 | 2010-09-15 | 重庆市中药研究院 | Method for separating glycoside chemical components from tibetan capillaris |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104478894A (en) * | 2014-12-30 | 2015-04-01 | 云南中医学院 | Gnetiolactone compound, as well as preparation method and application thereof |
| CN108042559A (en) * | 2018-01-08 | 2018-05-18 | 西安正大制药有限公司 | A kind of new Macrophylla dragon capsule optimizes pharmaceutical composition and its in analgesia, anti-inflammatory, in terms of cholagogic application |
| CN108042559B (en) * | 2018-01-08 | 2020-03-31 | 西安正大制药有限公司 | Optimized pharmaceutical composition of large-leaved gentian and dragon capsule and application of optimized pharmaceutical composition in aspects of analgesia, anti-inflammation and cholagogue |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104510747B (en) | A kind of new medicine use of iridoid glycoside | |
| CN103655590A (en) | Pharmaceutical composition containing gentiopicroside and preparation and usage thereof | |
| CN102210737A (en) | Sweet potato leaf extract and preparation method and use thereof | |
| CN102727486B (en) | Application of Inula lineariifolia lactone A in preparation of medicine for treating myocarditis | |
| Verhelst et al. | Acute hepatitis after treatment for hair loss with oral green tea extracts (Camellia Sinensis). | |
| CN103845354A (en) | Pharmaceutical composition containing gentiopicroside and its preparation and use | |
| KR19990015612A (en) | Hepatitis C Therapeutic Composition Containing Mixed Extracts of Hwangbaekpi and Matari Plants | |
| CN101134040B (en) | Application of forsythiaside in the preparation of medicament for treating or preventing acute and chronic liver damnification and liver fibrosis | |
| CN102532229B (en) | Pregnane glycoside compounds with orthoester groups and applications thereof | |
| CN103655591A (en) | Medicinal composition as well as preparation and application thereof | |
| CN103655589A (en) | Pharmaceutical composition and preparation and usage thereof | |
| CN100482266C (en) | Medical composite prepared by sarcandra and oldenlandia | |
| CN107383150A (en) | A kind of compound with antihepatitis activity and its production and use | |
| CN102940621B (en) | Application of methyl ferulic acid in preparation of medicine for preventing and curing hepatic fibrosis | |
| CN101829086B (en) | Application of aromatic carbamoyl dehydro-silibinin as medicament for treating viral hepatitis B | |
| Luo et al. | Establishment and evaluation of orthotopic hepatocellular carcinoma and drug-induced hepatocellular carcinoma in mice with spleen-deficiency syndrome in traditional Chinese medicine | |
| CN1969937B (en) | Pharmaceutical composition for treating hepatitis | |
| CN1977888B (en) | Medicinal composition of baicalin, ganoderma lucidum and salvia miltrorrhiza | |
| CN100493522C (en) | Medicinal composition of oxymatrine and polysaccharide | |
| CN108310362A (en) | Application of the carnosine in terms of hepatitis virus resisting | |
| CN103948780B (en) | A kind of medicine and capsule for constipation | |
| CN105982961A (en) | Traditional Chinese medicine composition with functions of resisting HIV infection and HBV infection and preparation method and application thereof | |
| CN102008588B (en) | Medicine composition for curing hepatic encephalopathy and hepatitis B | |
| CN1985988B (en) | Novel medicine composition for treating hepatic diseases | |
| CN108236607A (en) | Application of the talan dimer in the drug for preparing treatment liver related disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140611 |